GPTomics/bio-crispr-screens-in-vivo-screens

Version Compatibility

Reference examples tested with: MAGeCK 0.5.9+, MAGeCK-VISPR 0.5.6+, pandas 2.2+, numpy 1.26+.

Before using code patterns, verify installed versions match. If versions differ:

• CLI: mageck --version
• Reference focused libraries: Manguso 2017, Chen 2015, public Addgene aliquots

If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying.

In Vivo CRISPR Screen Analysis

"Design or analyze an in vivo CRISPR screen" -> Account for the dramatic bottleneck during animal implantation and tumor growth; use focused libraries; recover DNA from tumor explants; analyze with bottleneck-adjusted hit calling.

• CLI: mageck count + mageck test for standard analysis
• Special handling: bottleneck-adjusted coverage thresholds; per-tissue per-animal replicate structure

The In Vivo Bottleneck Problem

Why in vivo screens differ from in vitro:

| Constraint | In vitro | In vivo | |------------|----------|---------| | Cells per condition | 10M-100M (unlimited) | Limited by injection volume (1-5M cells typical) | | Implant -> early tumor cell count | N/A | 10-100x drop typical (~94% library complexity may survive in CD45+ TILs) | | Late tumor cell count | N/A | Further 5-10x reduction; final ~3.93 sgRNAs/gene | | Bottleneck per animal | None | Tens of millions of cells fail to engraft | | Library coverage achievable | 500-1000x | Often 50-100x effective at endpoint | | sgRNAs survivable | Full library | 80-94% in early tumors; 60-80% in late tumors |

Math: A 70,000-sgRNA library at 500x coverage requires 35M cells in pool. Most syngeneic models can implant 1-5M cells. Result: real coverage is 70x at best; effective coverage at endpoint is even lower after bottleneck.

Solution: Use focused libraries (500-3,000 genes; ~3,000-15,000 sgRNAs) to maintain reasonable coverage despite the bottleneck.

Focused Library Design for In Vivo

Manguso et al 2017 Nature 547:413 established the canonical in vivo CRISPR screen methodology with a focused library:

• 2,368 genes (kinases + cell surface proteins + immune factors)
• 4 sgRNAs per gene (~9,500 sgRNAs total)
• Targeted at immune-evasion biology in syngeneic mouse melanoma
• Identified PTPN2, NLRC5, CD47 as immune-evasion genes

Standard focused-library principles:

1. Gene selection: Define the biology to be tested (e.g., immune evasion, metastasis); restrict library to genes plausibly involved (kinases, surface proteins, regulators)
2. Library size: 500-3,000 genes; 3-6 sgRNAs/gene; total 3,000-18,000 sgRNAs
3. Coverage achievable: With 5M cells implanted, 100-300x coverage is achievable

Public focused libraries:

• Manguso 2017 immune library (Addgene)
• Joung 2017 pooled screen reference
• DepMap focused panels for specific pathways
• Custom: order from Twist via CRISPick or CRISPOR

CRISPR-StAR (Temporal Activation; Uijttewaal 2025)

Uijttewaal et al 2025 Nat Biotechnol 43(11):1848 (published online Dec 2024) introduced CRISPR-StAR (Staggered Activation Reporter), which uses inducible Cas9 expression to delay gene editing until after cells have engrafted in the animal.

How it works:

1. Library is delivered into cells with inducible (Dox-controlled) Cas9
2. Cells are implanted in animal at MOI 0.3
3. Cells engraft into tumor (no editing yet); library complexity preserved
4. Days 5-7 post-implantation: induce Cas9 with doxycycline
5. Editing begins; screen proceeds for additional weeks
6. Tumor harvest, DNA extraction, sequencing

Quantified gain: CRISPR-StAR enables genome-scale in vivo screens (vs focused libraries) by generating intrinsic per-clone controls; outperforms conventional in vivo screens in therapy-resistant mouse melanoma models (Uijttewaal 2025).

Syngeneic vs Xenograft vs PDX

| Model | Immune system | Use case | |-------|---------------|----------| | Syngeneic (e.g., B16 melanoma in C57BL/6) | Intact mouse immunity | Tumor-immune interaction; checkpoint biology | | Xenograft (human cancer line in NSG) | Absent / impaired | Tumor cell-intrinsic biology; drug response in human cells | | PDX (patient-derived xenograft) | Absent / impaired | Patient-specific biology; therapy testing | | Humanized mouse | Reconstituted human immunity | Tumor-immune in human context (limited) | | Organoid in vivo | None (in vitro) | Tumor cell-intrinsic in 3D structure |

Decision rule: For immune-targeting drug screens, use syngeneic. For human-cancer cell-intrinsic biology, use xenograft. For patient-specific drug screens, use PDX. Each requires different cell numbers and bottleneck planning.

Tumor DNA Extraction and Sequencing

Goal: Recover sufficient sgRNA-containing DNA from tumor explants for sequencing.

Approach: Dissect tumor; lyse with proteinase K; extract genomic DNA; amplify the sgRNA locus by PCR; sequence on MiSeq / NextSeq / NovaSeq.

# Typical PCR + sequencing parameters for in vivo screens
# Per-tumor DNA: 0.5-5 mg yield from typical syngeneic tumor
# Per-sample sequencing depth: ≥500 reads/sgRNA at endpoint (lower than in vitro 300+)
# Multiple animals per condition (n=5-10) to account for clonal variation

# mageck count for in vivo
mageck count \
    --list-seq library.csv \
    --sample-label Plasmid,Animal1,Animal2,Animal3,Animal4,Animal5 \
    --fastq Plasmid.fq.gz A1.fq.gz A2.fq.gz A3.fq.gz A4.fq.gz A5.fq.gz \
    --norm-method median \
    --output-prefix in_vivo_screen

Hit Calling for In Vivo

Goal: Identify per-gene fitness effects despite high inter-animal variability.

Approach: Each animal is a "replicate" with high variance due to clonal dynamics. Use MAGeCK MLE with animal-as-batch covariate, or run MAGeCK RRA per animal and meta-analyze.

# Option A: MAGeCK MLE with batch covariate
cat > in_vivo_design.txt <<EOF
Samples         baseline    tumor   animal_2  animal_3  animal_4  animal_5
Plasmid         1           0       0         0         0         0
Animal1         1           1       0         0         0         0
Animal2         1           1       1         0         0         0
Animal3         1           1       0         1         0         0
Animal4         1           1       0         0         1         0
Animal5         1           1       0         0         0         1
EOF

mageck mle \
    --count-table in_vivo_screen.count.txt \
    --design-matrix in_vivo_design.txt \
    --output-prefix in_vivo_mle

Per-animal RRA + meta-analysis:

import pandas as pd

# Run mageck test on each animal vs plasmid
# Combine with Stouffer's Z method
from scipy.stats import norm

def meta_analyze_animals(per_animal_results):
    '''per_animal_results: list of MAGeCK gene_summary.txt per animal.'''
    merged = pd.concat([df.assign(animal=i) for i, df in enumerate(per_animal_results)])
    grouped = merged.groupby('id')
    meta = grouped.apply(lambda g: pd.Series({
        'mean_neg_score': g['neg|score'].mean(),
        'stouffer_z': norm.ppf(g['neg|p-value']).sum() / (len(g) ** 0.5),
        'animals_significant': (g['neg|fdr'] < 0.05).sum(),
        'n_animals': len(g)
    }))
    return meta.sort_values('stouffer_z')

Failure Modes

Clonal dominance from low complexity

Trigger: Implanted cells lack sufficient library complexity; a few clones dominate the tumor. Mechanism: Inter-animal stochasticity in cell engraftment creates founder effects. Symptom: Per-animal hit lists vary dramatically; no genes appear across all animals. Fix: Use focused library to maintain coverage; increase animals per condition (n=10+); use CRISPR-StAR to delay bottleneck.

Tumor DNA extraction yields no sgRNA reads

Trigger: Wrong library or library not amplified well from tumor DNA. Mechanism: PCR primers don't match the sgRNA flanking; or insufficient DNA template. Symptom: Low mapping rate (<10%); few sgRNAs detected per tumor. Fix: Verify library plasmid sequence; design primers specific to lentiviral cassette; use 10-100 ng input DNA + 25 PCR cycles.

In vivo PR-AUC against CEGv2 is poor

Trigger: Tumor biology differs from in vitro CEGv2 calibration; not all essentials are essential in animal context. Mechanism: Cells in vivo have different growth conditions (nutrients, hypoxia, immune pressure) than in vitro; CEGv2 calibration assumes in vitro context. Symptom: CEGv2 PR-AUC <0.5 in vivo despite high in vitro PR-AUC. Fix: Use cell-type-and-context-specific essentialome (e.g., a corresponding in vitro screen of the same cell type) as a baseline; in vivo essentialome is biology-dependent.

Pre-screen Cas9 selection failure

Trigger: Cas9-positive cells were not selected before implantation; library has Cas9-negative escapers. Mechanism: Cas9-negative cells carry sgRNA but no editing; persist in tumor without biological perturbation. Symptom: Specific essentiality signals weak; PR-AUC low. Fix: Always select Cas9-positive cells (FACS or selection) before infection; verify by Cas9 IHC or flow.

Inter-animal variability dominates hit calling

Trigger: Limited animals per condition (n=3-5); each has high variance. Mechanism: Per-animal clonal dynamics produce different sgRNA distributions; no consistent signal across few animals. Symptom: MAGeCK p-values inflated; FDR uncalibrated. Fix: Increase animals per condition to 10+; use meta-analysis across animals (Stouffer); validate top hits in arrayed format with n=10 mice each.

Tumor heterogeneity destroys screen signal

Trigger: Spontaneously arising mutations in some tumor regions create non-clonal heterogeneity. Mechanism: Tumor heterogeneity is genuine biology; not all cells in tumor are descendants of original engrafted cells. Symptom: Per-region sequencing shows different sgRNA distributions within same tumor. Fix: Sample multiple tumor regions; or use whole-tumor genomic DNA pooling (averages out heterogeneity).

Quantitative Thresholds

| Threshold | Value | Source / Rationale | |-----------|-------|--------------------| | Cells per animal | 1-5M typical for syngeneic; 5-10M for xenograft | Tumor model dependent | | sgRNAs per gene in library (focused) | 4-6 | Standard convention | | Library size for in vivo focused | 3,000-15,000 sgRNAs | Maintainable coverage | | Coverage at endpoint | ≥50x, ideally 100-200x | Lower than in vitro 500x | | Animals per condition | 10+ for hit-calling; 5 minimum | Inter-animal variability | | Animals per condition for arrayed validation | 10 | Tighter signal needed | | In vivo CEGv2 PR-AUC | >0.4 (context-dependent) | Lower than in vitro 0.7 | | Late tumor sgRNA-per-gene | ~3.93 typical | Empirical from literature | | Days to harvest (tumor) | 12-21 days post-implant | Time for selection to manifest |

Common Errors

| Error / symptom | Cause | Solution | |-----------------|-------|----------| | No hits | Library complexity collapsed | Use focused library or CRISPR-StAR | | Per-animal hit lists differ | Clonal dominance | Use focused library; increase animals | | Low CEGv2 PR-AUC | Context-specific essentialome | Use in vivo-specific reference set | | Low mapping rate | Wrong sequencing primers | Verify library lentiviral architecture | | Coverage at endpoint <50x | Implantation bottleneck | Increase cells implanted; focused library |

References

• Manguso RT et al. 2017. Nature 547:413. In vivo CRISPR screen for immune evasion; canonical focused-library design.
• Chen S et al. 2015. Cell 160:1246. Original in vivo Cas9 screening methodology.
• Aoki Y et al. 2023. Cancer Gene Therapy (doi 10.1038/s41417-023-00664-5). Clonal dynamics limit selection detection in in-vivo CRISPR screens. (Earlier "Sci Adv 9:eadg2451" attribution could not be verified.)
• Uijttewaal ECH et al. 2025. Nat Biotechnol 43:1848 (online Dec 2024). CRISPR-StAR intrinsic-control screening for in vivo models.
• Pacini C et al. 2024. Nat Commun 15:1230. DepMap screening benchmark including in vivo.

Related Skills

• crispr-screens/library-design - Focused library design for in vivo
• crispr-screens/mageck-analysis - MAGeCK MLE with animal-as-batch covariate
• crispr-screens/hit-calling - Per-animal meta-analysis strategies
• crispr-screens/screen-qc - In-vivo-specific QC thresholds
• crispr-screens/batch-correction - Animal cohort as batch in MLE
• crispr-screens/combinatorial-screens - In vivo combinatorial screens
• crispr-screens/copy-number-correction - Cancer-line in vivo screens
• pathway-analysis/go-enrichment - Functional analysis of in vivo hits